Back HCV Treatment

DDW 2016: ABT-493 + ABT-530 Cures Most Hepatitis C Patients in SURVEYOR Studies

A coformulation of AbbVie's experimental next-generation direct-acting antiviral agents ABT-493 and ABT-530 was well-tolerated and led to sustained virological response in 97% or more of patients with all hepatitis C virus (HCV) genotypes in a set of studies reported this week at the 2016 Digestive Disease Week meeting in San Diego.

alt

Read more: